These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34951111)

  • 21. HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USA.
    de Mulder M; York VA; Wiznia AA; Michaud HA; Nixon DF; Holguin A; Rosenberg MG
    HIV Med; 2014 Mar; 15(3):135-43. PubMed ID: 24112468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proviral DNA as a Target for HIV-1 Resistance Analysis.
    Lübke N; Di Cristanziano V; Sierra S; Knops E; Schülter E; Jensen B; Oette M; Lengauer T; Kaiser R
    Intervirology; 2015; 58(3):184-9. PubMed ID: 26139571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brief Report: Comparative Analysis of Pre-existing HIV Drug Resistance Mutations in Proviral DNA Using Next-Generation Sequencing and Routine HIV RNA Genotyping.
    Gaitan NC; D'Antoni ML; Acosta RK; Gianella S; Little SJ; Chaillon A
    J Acquir Immune Defic Syndr; 2023 Jul; 93(3):213-218. PubMed ID: 36961945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana.
    Moraka NO; Garcia-Broncano P; Hu Z; Ajibola G; Bareng OT; Pretorius-Holme M; Maswabi K; Maphorisa C; Mohammed T; Gaseitsiwe S; VanZyl GU; Kuritzkes DR; Lichterfeld M; Moyo S; Shapiro RL
    AIDS; 2021 Dec; 35(15):2413-2421. PubMed ID: 34324451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Added Value of Next Generation over Sanger Sequencing in Kenyan Youth with Extensive HIV-1 Drug Resistance.
    Novitsky V; Nyandiko W; Vreeman R; DeLong AK; Manne A; Scanlon M; Ngeresa A; Aluoch J; Sang F; Ashimosi C; Jepkemboi E; Orido M; Hogan JW; Kantor R;
    Microbiol Spectr; 2022 Dec; 10(6):e0345422. PubMed ID: 36445146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinctive Drug-resistant Mutation Profiles and Interpretations of HIV-1 Proviral DNA Revealed by Deep Sequencing in Reverse Transcriptase.
    Yin QQ; Li ZP; Zhao H; Pan D; Wang Y; Xu WS; Xing H; Feng Y; Jiang SB; Shao YM; Ma LY
    Biomed Environ Sci; 2016 Apr; 29(4):239-47. PubMed ID: 27241734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protease and gag diversity and drug resistance mutations among treatment-naive Mexican people living with HIV.
    Climaco-Arvizu S; Flores-López V; González-Torres C; Gaytán-Cervantes FJ; Hernández-García MC; Zárate-Segura PB; Chávez-Torres M; Tesoro-Cruz E; Pinto-Cardoso SM; Bekker-Méndez VC
    BMC Infect Dis; 2022 May; 22(1):447. PubMed ID: 35538426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City, China.
    Liu J; Li C; Sun Y; Fu C; Wei S; Zhang X; Ma J; Zhao Q; Huo Y
    Sci Rep; 2024 May; 14(1):10620. PubMed ID: 38724547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.
    Ceccarelli L; Salpini R; Moudourou S; Cento V; Santoro MM; Fokam J; Takou D; Nanfack A; Dori L; Torimiro J; Sarmati L; Andreoni M; Perno CF; Colizzi V; Cappelli G
    J Med Virol; 2012 May; 84(5):721-7. PubMed ID: 22431019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat".
    Fokam J; Sosso SM; Yagai B; Billong SC; Djubgang Mbadie RE; Kamgaing Simo R; Edimo SV; Nka AD; Tiga Ayissi A; Yimga JF; Takou D; Moudourou S; Ngo Nemb M; Nfetam Elat JB; Santoro MM; Perno CF; Colizzi V; Ndjolo A
    AIDS Res Ther; 2019 Nov; 16(1):36. PubMed ID: 31744517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing.
    Rauschning D; Ehren I; Heger E; Knops E; Fätkenheuer G; Suárez I; Lehmann C
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1C proviral DNA for detection of drug resistance mutations.
    Huruy K; Mulu A; Liebert UG; Maier M
    PLoS One; 2018; 13(10):e0205119. PubMed ID: 30286160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High discordance in blood and genital tract HIV-1 drug resistance in Indian women failing first-line therapy.
    Saravanan S; Gomathi S; Delong A; Kausalya B; Sivamalar S; Poongulali S; Brooks K; Kumarasamy N; Balakrishnan P; Solomon SS; Cu-Uvin S; Kantor R
    J Antimicrob Chemother; 2018 Aug; 73(8):2152-2161. PubMed ID: 29800305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited evolution but increasing trends of primary non-nucleoside reverse transcriptase inhibitor resistance mutations in therapy-naive HIV-1-infected individuals in India.
    Neogi U; Gupta S; Palchaudhuri R; Rao SD; Shastri S; Diwan V; Laishram RS; De Costa A; Shet A
    Antivir Ther; 2014; 19(8):813-8. PubMed ID: 24699043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation.
    Li Y; Etemad B; Dele-Oni R; Sharaf R; Gao C; Lichterfeld M; Li JZ
    AIDS; 2021 Jun; 35(7):1015-1020. PubMed ID: 33635848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy.
    Etiebet MA; Shepherd J; Nowak RG; Charurat M; Chang H; Ajayi S; Elegba O; Ndembi N; Abimiku A; Carr JK; Eyzaguirre LM; Blattner WA
    AIDS; 2013 Feb; 27(4):553-61. PubMed ID: 23079810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
    Kityo C; Thompson J; Nankya I; Hoppe A; Ndashimye E; Warambwa C; Mambule I; van Oosterhout JJ; Wools-Kaloustian K; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Paton NI;
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e45-e54. PubMed ID: 28129253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance in children and adolescents with HIV in Panama.
    Ventosa-Cubillo J; Pinzón R; González-Alba JM; Estripeaut D; Navarro ML; Holguín Á
    J Antimicrob Chemother; 2023 Feb; 78(2):423-435. PubMed ID: 36454248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.
    Seu L; Mulenga LB; Siwingwa M; Sikazwe I; Lambwe N; Guffey MB; Chi BH
    J Med Virol; 2015 Jul; 87(7):1149-57. PubMed ID: 25754408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.